HC Wainwright & Co. Reiterates Neutral on Arcus Biosciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated a Neutral rating for Arcus Biosciences (NYSE:RCUS) and maintained a $20 price target.
October 24, 2024 | 7:21 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating for Arcus Biosciences and maintained a $20 price target, indicating no expected significant short-term price movement.
The reiteration of a Neutral rating and maintenance of the $20 price target by HC Wainwright & Co. suggests that the analyst does not foresee significant short-term changes in the stock's price. This indicates a stable outlook without any major catalysts for upward or downward movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100